Patents by Inventor Jeffrey A. Herron
Jeffrey A. Herron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813593Abstract: A heterogeneous catalyst comprising a support and gold, wherein: (i) said support comprises alumina, (ii) said catalyst comprises from 0.1 to 5 wt % of gold, (iii) at least 90 wt % of the gold is in the outer 60% of catalyst volume, and (iv) particles of the catalyst have an average diameter from 200 microns to 30 mm; wherein weight percentages are based on weight of the catalyst.Type: GrantFiled: June 20, 2019Date of Patent: November 14, 2023Assignees: Rohm and Haas Company, Dow Global Technologies LLCInventors: Kirk W. Limbach, Christopher D. Frick, Dmitry A. Krapchetov, Wen -Sheng Lee, Victor J. Sussman, Jeffrey A. Herron
-
Publication number: 20230321637Abstract: A catalyst comprising a noble metal disposed on a support. The noble metal is present in an amount ranging from 0.1 wt % to 10 wt % relative to the total weight of the catalyst. The support comprises at least 50 wt % silicon carbide relative to the total weight of the support. The silicon carbide has a surface area of at least 5 m2/g. A method for preparing methyl methacrylate from methacrolein and methanol using the catalyst is also disclosed.Type: ApplicationFiled: July 13, 2021Publication date: October 12, 2023Inventors: Alexey Kirilin, Kirk W. Limbach, Wen Sheng Lee, Jeffrey A. Herron, Victor J. Sussman
-
Publication number: 20230310841Abstract: Techniques are disclosed for defining a homeostatic window for controlling delivery of electrical stimulation therapy to a patient. In one example, a method includes generating and delivering electrical stimulation therapy to tissue of a patient via electrodes. Further, the method includes adjusting a level of a parameter of the electrical stimulation therapy such that a signal of the patient is not less than a lower bound and not greater than an upper bound. The lower bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce one or more symptoms of a disease while the patient was receiving medication for reduction of the one or more symptoms. Further, the upper bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce the one or more symptoms when the patient was not receiving the medication.Type: ApplicationFiled: June 5, 2023Publication date: October 5, 2023Inventors: Scott R. Stanslaski, Thomas Adamski, Duane L. Bourget, Timothy J. Denison, Benjamin P. Isaacson, Eric J. Panken, Jeffrey Herron
-
Patent number: 11691942Abstract: A method for preparing methyl methacrylate from methacrolein and methanol. The process comprises contacting in a reactor a mixture comprising methacrolein, methanol and oxygen with a heterogeneous catalyst comprising a support and a noble metal, wherein said catalyst has an average diameter of at least 200 microns, liquid and gaseous reactants flow downward in the reactor and wherein the continuous phase in the reactor is a gas which has no more than 7.5 mol % oxygen at reactor inlets.Type: GrantFiled: June 25, 2018Date of Patent: July 4, 2023Assignees: Dow Global Technologies LLC, Rohm and Haas CompanyInventors: Kirk W. Limbach, Dmitry A. Krapchetov, Daniel A. Hickman, Jeffrey Herron
-
Patent number: 11666750Abstract: Techniques are disclosed for defining a homeostatic window for controlling delivery of electrical stimulation therapy to a patient. In one example, a method includes generating and delivering electrical stimulation therapy to tissue of a patient via electrodes. Further, the method includes adjusting a level of a parameter of the electrical stimulation therapy such that a signal of the patient is not less than a lower bound and not greater than an upper bound. The lower bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce one or more symptoms of a disease while the patient was receiving medication for reduction of the one or more symptoms. Further, the upper bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce the one or more symptoms when the patient was not receiving the medication.Type: GrantFiled: November 30, 2020Date of Patent: June 6, 2023Assignee: Medtronic, Inc.Inventors: Scott R. Stanslaski, Thomas Adamski, Duane L. Bourget, Timothy J. Denison, Benjamin P. Isaacson, Eric J. Panken, Jeffrey Herron
-
Publication number: 20230113685Abstract: A catalyst comprising noble metal particles and titanium-containing particles. The noble metal particles and titanium-containing particles are disposed on an outer surface of a support. At least 20% by weight of the total weight of noble metal particles are adjacent to at least one titanium-containing particle. The noble metal particles have an average diameter of less than 15 nm, and the catalyst has an average diameter of at least 200 microns. A method for preparing methyl methacrylate from methacrolein and methanol using the catalyst is also disclosed.Type: ApplicationFiled: March 15, 2021Publication date: April 13, 2023Inventors: Kirk W. Limbach, Christopher D. Frick, Wen -Sheng Lee, Victor J. Sussman, Dmitry A. Krapchetov, Jeffrey A. Herron
-
Patent number: 11617887Abstract: Systems and methods for promoting neuroplasticity in a brain of a subject to improve and/or restore neural function are disclosed herein. One such method includes detecting residual movement and/or muscular activity in a limb of the subject, such as a paretic limb. The method further includes generating a stimulation pattern based on the detected movement and/or muscular activity, and stimulating the brain of the subject with the stimulation pattern. It is expected that delivering stimulation based on the detected residual movement and/or muscular activity of the limb will induce neuroplasticity for restoring neural function, such as control of the limb. A second method involves detecting brain signals and delivering contingent stimulation. A third method involves delivering pairs of successive stimulus patterns to two brain sites, controlled either by preprogrammed sequences or contingent on neural or muscular activity or movement.Type: GrantFiled: April 19, 2019Date of Patent: April 4, 2023Assignee: University of Washington and Seattle Children's Hospital Children's Research InstituteInventors: Rajesh P. N. Rao, Jeffrey G. Ojemann, Eberhard E. Fetz, Chet T. Moritz, Jeffrey Herron
-
Patent number: 11577225Abstract: A heterogeneous catalyst comprising a support and a noble metal, wherein said support comprises silicon, and wherein said catalyst comprises from 0.1 to 40 mol % titanium and from 0.1 to 10 mol % of at least one noble metal.Type: GrantFiled: December 13, 2018Date of Patent: February 14, 2023Assignees: Dow Global Technologies LLC, Rohm and Haas Co.Inventors: Christopher D. Frick, Jeffrey A. Herron, Kirk W. Limbach, Wen Sheng Lee, Victor J. Sussman
-
Publication number: 20220395815Abstract: A method for preparing a heterogeneous catalyst. The method comprises steps of: (a) combining (i) a support, (ii) an aqueous solution of a noble metal compound and (iii) a C2-C18 thiol comprising at least one hydroxyl or carboxylic acid substituent; to form a wet particle and (b) removing water from the wet particle by drying followed by calcination to produce the catalyst.Type: ApplicationFiled: August 17, 2022Publication date: December 15, 2022Inventors: Victor J. Sussman, Wen-Sheng Lee, Jeffrey A. Herron, D. Wayne Blaylock, Daniel J. Arriola, Andrew T. Heitsch, Alexey Kirilin, Heidi Clements, Abrin L. Schmucker, Daniel A. Hickman
-
Patent number: 11498057Abstract: A heterogeneous catalyst comprising a support and gold, wherein: (i) said support comprises titanium, (ii) said catalyst comprises from 0.1 to 5 wt % of gold, (iii) at least 90 wt % of the gold is in the outer 60% of catalyst volume, and (iv) particles of the catalyst have an average diameter from 200 microns to 30 mm; wherein weight percentages are based on weight of the catalyst.Type: GrantFiled: June 20, 2019Date of Patent: November 15, 2022Assignees: Rohm and Haas Company, Dow Global Technologies LLCInventors: Kirk W. Limbach, Christopher D. Frick, Dmitry A. Krapchetov, Wen-Sheng Lee, Victor J. Sussman, Jeffrey A. Herron
-
Publication number: 20220241591Abstract: Systems and methods for deep brain stimulation using kinematic feedback in accordance with embodiments of the invention are illustrated. One embodiment includes a deep brain stimulation system, including an implantable neurostimulator, a first inertial measurement unit (IMU), a second IMU, and a controller, where the controller is communicatively coupled to the implantable neurostimulator, the first IMU, and the second IMU, and where the controller is configured to obtain kinematic data from the first IMU and the second IMU, identify an abnormal movement event based on the kinematic data, and modify deep brain stimulation provided by the implantable neurostimulator based on the identified abnormal movement event.Type: ApplicationFiled: February 1, 2022Publication date: August 4, 2022Applicants: The Board of Trustees of the Leland Stanford Junior University, University of WashingtonInventors: Helen Bronte-Stewart, Yasmine Kehnemouyi, Matthew Petrucci, Jeffrey Herron, Johanna O'Day
-
Publication number: 20220241594Abstract: Systems and methods for deep brain stimulation using beta burst feedback in accordance with embodiments of the invention are illustrated. One embodiment includes a deep brain stimulation system, including a neurostimulator, and a controller, where the controller is communicatively coupled to the neurostimulator and configured to obtain a plurality of neural activity signals from the neurostimulator, identify beta bursts within each neural activity signal, classify identified beta bursts as pathological or normal, and modify stimulation provided by the neurostimulator based on the classified beta bursts.Type: ApplicationFiled: February 1, 2022Publication date: August 4, 2022Applicants: The Board of Trustees of the Leland Stanford Junior University, University of WashingtonInventors: Helen Bronte-Stewart, Matthew Petrucci, Ross Anderson, Raumin Neuville, Jordan Parker, Jeffrey Herron
-
Patent number: 11291843Abstract: Devices, systems, and techniques are described for transitioning between different groups of electrical stimulation programs. For example, a system may control delivery of second electrical stimulation defined by one or more second programs of a second group of stimulation programs on a time-interleaved basis with first electrical stimulation defined by one or more first programs of the first group of stimulation programs. The system may change a first ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a first period of time to a second ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a second period of time.Type: GrantFiled: December 7, 2018Date of Patent: April 5, 2022Assignee: Medtronic, Inc.Inventors: Duane L. Bourget, David E. Linde, Robert Devine, Benjamin P. Isaacson, Jeffrey Herron
-
Publication number: 20210363094Abstract: A method for preparing methyl methacrylate from methacrolein and methanol. The process comprises contacting in a reactor a mixture comprising methacrolein, methanol and oxygen with a heterogeneous catalyst comprising a support and a noble metal, wherein said catalyst has an average diameter of at least 200 microns, liquid and gaseous reactants flow downward in the reactor and wherein the continuous phase in the reactor is a gas which has no more than 7.5 mol % oxygen at reactor inlets.Type: ApplicationFiled: June 25, 2018Publication date: November 25, 2021Inventors: Kirk W. Limbach, Dmitry A. Krapchetov, Daniel A. Hickman, Jeffrey Herron
-
Patent number: 11111204Abstract: A method for preparing methyl methacrylate from methacrolein and methanol; said method comprising contacting a mixture comprising methacrolein, methanol and oxygen with a heterogeneous catalyst comprising a support and a noble metal, wherein said support comprises silicon, and wherein said catalyst comprises from 0.1 to 40 mol % titanium and from 0.1 to 10 mol % of at least one noble metal.Type: GrantFiled: December 13, 2018Date of Patent: September 7, 2021Assignees: Dow Global Technologies LLC, Rohm and Haas CompanyInventors: Christopher D. Frick, Jeffrey A. Herron, Kirk W. Limbach, Wen Sheng Lee, Victor J. Sussman
-
Publication number: 20210121856Abstract: A heterogeneous catalyst comprising a support and gold, wherein: (i) said support comprises alumina, (ii) said catalyst comprises from 0.1 to 5 wt % of gold, (iii) at least 90 wt % of the gold is in the outer 60% of catalyst volume, and (iv) particles of the catalyst have an average diameter from 200 microns to 30 mm; wherein weight percentages are based on weight of the catalyst.Type: ApplicationFiled: June 20, 2019Publication date: April 29, 2021Inventors: Kirk W. Limbach, Christopher D. Frick, Dmitry A. Krapchetov, Wen -Sheng Lee, Victor J. Sussman, Jeffrey A. Herron
-
Publication number: 20210113997Abstract: A heterogeneous catalyst comprising a support and gold, wherein: (i) said support comprises titanium, (ii) said catalyst comprises from 0.1 to 5 wt % of gold, (iii) at least 90 wt % of the gold is in the outer 60% of catalyst volume, and (iv) particles of the catalyst have an average diameter from 200 microns to 30 mm; wherein weight percentages are based on weight of the catalyst.Type: ApplicationFiled: June 20, 2019Publication date: April 22, 2021Inventors: Kirk W. Limbach, Christopher D. Frick, Dmitry A. Krapchetov, Wen -Sheng Lee, Victor J. Sussman, Jeffrey A. Herron
-
Publication number: 20210093851Abstract: Techniques are disclosed for defining a homeostatic window for controlling delivery of electrical stimulation therapy to a patient. In one example, a method includes generating and delivering electrical stimulation therapy to tissue of a patient via electrodes. Further, the method includes adjusting a level of a parameter of the electrical stimulation therapy such that a signal of the patient is not less than a lower bound and not greater than an upper bound. The lower bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce one or more symptoms of a disease while the patient was receiving medication for reduction of the one or more symptoms. Further, the upper bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce the one or more symptoms when the patient was not receiving the medication.Type: ApplicationFiled: November 30, 2020Publication date: April 1, 2021Inventors: Scott R. Stanslaski, Thomas Adamski, Duane L. Bourget, Timothy J. Denison, Benjamin P. Isaacson, Eric J. Panken, Jeffrey Herron
-
Patent number: 10865179Abstract: A method for preparing methyl methacrylate from methacrolein and methanol. The method comprises contacting a mixture comprising methacrolein, methanol and oxygen with a heterogeneous catalyst comprising a support and a noble metal, wherein oxygen concentration at a reactor outlet is from 1 to 7.5 mol % and wherein pH at a reactor outlet is no greater than 7.5.Type: GrantFiled: September 12, 2018Date of Patent: December 15, 2020Assignees: Dow Global Technologies, LLC, Rohm and Haas CompanyInventors: Jeffrey Herron, Daniel J. Arriola, D. Wayne Blaylock, Wen-Sheng Lee, Victor Sussman, Daniel A. Hickman, Kirk W. Limbach
-
Patent number: 10864368Abstract: Techniques are disclosed for defining a homeostatic window for controlling delivery of electrical stimulation therapy to a patient. In one example, a method includes generating and delivering electrical stimulation therapy to tissue of a patient via electrodes. Further, the method includes adjusting a level of a parameter of the electrical stimulation therapy such that a signal of the patient is not less than a lower bound and not greater than an upper bound. The lower bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce one or more symptoms of a disease while the patient was receiving medication for reduction of the one or more symptoms. Further, the upper bound is determined to be the magnitude of the signal while receiving electrical stimulation therapy sufficient to reduce the one or more symptoms when the patient was not receiving the medication.Type: GrantFiled: September 25, 2017Date of Patent: December 15, 2020Assignee: Medtronic, Inc.Inventors: Scott R. Stanslaski, Thomas Adamski, Duane L. Bourget, Timothy J. Denison, Benjamin P. Isaacson, Eric J. Panken, Jeffrey Herron